LAUSR

Introduction: Morbidity and mortality of cancer patients with COVID-19 have not been examined The goal of thisanalysis was to compare the demographics and clinical characteristics of COVID-19 cancer patients to the rest ofCOVID-19 patients and assess whether cancer is associated with morbidity or mortality Methods: COVID-19-positive patients with an inpatient or emergency encounter at the Mount Sinai Health Systembetween 03/01/20-05/27/20 were included in the analysis Patients were compared across cancer status(noncancer, non-solid cancers, and solid cancers) on demographics and clinical characteristics Multivariable logisticregressions were used to model the associations of cancer status with sepsis, acute venous thromboembolism, andmortality Results: There were 5,516 COVID-19 positive patients included, 96 (1 7%) with non-solid cancers and 325 (5 8%)with solid cancers Those with solid cancers were significantly older (mean: 70 9 vs 63 8 and 63 2 years) and morelikely to be non-Hispanic Black (26 5% vs 23 9% and 22 9%) than noncancer and non-solid cancers patients Those with cancer had significantly more additional comorbid conditions (42 7% and 49 8% ≥2 comorbidities for non-solidand solid cancers, vs 30 4% for noncancer) Platelets (mean [noncancer]: 223 8, mean [non-solid cancer]: 182 6, mean [solid cancer]: 218 3 × 10 /μL), white blood cell count (mean [noncancer]: 8 4, mean [non-solid cancer]: 6 7, mean [solid cancer]: 8 0 × 10 /μL), hemoglobin (mean [noncancer]: 13 1, mean [non-solid cancer]: 11 2, mean [solidcancer]: 12 0 g/dL), and red blood cell count (mean [non-cancer]: 4 5, mean [non-solid cancer]: 3 7, mean [solid cancer]: 4 1 × 10 /μL) were significantly lower in cancer patients, and lowest in those with non-solid cancers Afteradjustment and compared to noncancer patients, those with cancer had significantly higher risk of acute venousthromboembolism (OR : 1 77, 95% CI: 1 01-3 09) and sepsis (OR : 1 34, 95% CI: 1 09-1 64) There was nosignificant difference in mortality (OR : 1 02, 95% CI: 0 81-1 29) There was no significant difference in alloutcomes for solid and non-solid cancer types Conclusion: COVID-19 patients with cancer, particularly solid tumors, are significantly older, with morecomorbidities than those without cancer There was no statistically significant difference in mortality for COVID-19patients with cancer, but a significantly higher risk of thromboembolism and sepsis Further research into the effectthat cancer treatments may have in inflammatory and immune responses to COVID is warranted